Proteomic signature predicts the metastatic risk of primary cutaneous squamous cell carcinomas.

Authors

Ali Azimi, Ellis Patrick, Rachel Teh, Tara Sholji, Raquel Ruiz Araujo, Jennifer Kim, Pablo Fernandez-Penas

Published in

The Journal of investigative dermatology. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Cutaneous squamous cell carcinoma (cSCC) is a heterogeneous skin malignancy worldwide. While most tumours are effectively treated by surgical excision, between 5% and 37% of biologically aggressive cases metastasise to regional lymph nodes or distant organs. Identifying tumours at risk of metastasis remains challenging, particularly for the 16-30% of cases lacking clear clinical or histopathological high-risk features. In this study, we applied a mass spectrometry-based proteomic approach to profile archival primary cSCC samples with and without confirmed metastasis. A total of 4,819 protein groups were identified, of which 284 were differentially abundant between the groups. The differential abundance of a subset of proteins was further validated in silico using independent transcriptomic datasets. These proteins were enriched in pathways associated with metastatic hallmarks, including reduced apoptosis, decreased cell adhesion and differentiation, and increased angiogenesis and keratinocyte migration. Classification analysis using support vector machine models achieved 88.66% accuracy in predicting metastatic potential. Collectively, these findings demonstrate the potential of proteomics to improve metastatic risk stratification and guide clinical management of cSCC, ultimately supporting better patient outcomes.

PMID:
42772590
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.